Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.57 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.57 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 7/20 | 0.41 |
| ▸ | PPARD | Q03181 | 7/20 | 0.41 |
| ▸ | PPARA | Q07869 | 7/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TLR2 | O60603 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | FABP4 | P15090 | 2/20 | 0.41 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.41 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16421113 | 0.89 | GPR84 (0.67) | GPR84FFAR1FFAR4CAMK2ATSHR | |
| SCHEMBL16384907 | 0.86 | GPR84 (0.61) | GPR84FFAR1FFAR4TSHRLMNA | |
| SCHEMBL17381370 | 0.82 | GPR84 (0.57) | GPR84FFAR1FFAR4CAMK2ATSHR | |
| SCHEMBL6829206 | 0.81 | CYP4F2 (0.41) | GPR84FFAR1FFAR4TSHRLMNA | |
| SCHEMBL16421115 | 0.80 | TSHR (0.60) | GPR84FFAR1FFAR4TSHRLMNA | |
| SCHEMBL16418484 | 0.80 | MAPT (0.62) | LMNAPPARGPPARDPPARAPTPN1 | |
| SCHEMBL16418497 | 0.80 | HSD17B10 (0.62) | GPR84FFAR1FFAR4TSHRLMNA | |
| SCHEMBL7775190 | 0.78 | FFAR1 (0.46) | GPR84FFAR1FFAR4CAMK2ATSHR | |
| SCHEMBL18748755 | 0.78 | FFAR1 (0.46) | GPR84FFAR1FFAR4CAMK2ATSHR | |
| SCHEMBL31377625 | 0.78 | GPR84 (0.65) | GPR84FFAR1FFAR4TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037378-B2 | Variant CD58 domains and uses thereof | NOVARTIS AG (CH) | 2024-07-16 | — | — | US | disclosed |
| US-20240066132-A1 | NOVEL FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | NOVARTIS AG (CH) | 2024-02-29 | — | — | US | disclosed |
| US-20240025993-A1 | CD19 BINDING MOLECULES AND USES THEREOF | NOVARTIS AG (CH) | 2024-01-25 | — | — | US | disclosed |
| US-11752211-B2 | Fatty acids and their use in conjugation to biomolecules | NOVARTIS AG (CH) | 2023-09-12 | — | — | US | disclosed |
| US-20170233443-A1 | CYCLIC POLYPEPTIDES FOR THE TREATMENT OF HEART FAILURE | NOVARTIS AG (CH) | 2017-08-17 | — | — | US | disclosed |
| US-9683019-B2 | Cyclic polypeptides for the treatment of heart failure | NOVARTIS AG (CH) | 2017-06-20 | — | — | US | disclosed |
| US-20170119851-A1 | METHODS OF TREATING ANOREXIA | NOVARTIS AG (CH) | 2017-05-04 | — | — | US | disclosed |
| US-20170107248-A1 | SITE SPECIFIC PROTEIN MODIFICATIONS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2017-04-20 | — | — | US | disclosed |
| US-20160166634-A1 | BIOCONJUGATES OF SYNTHETIC APELIN POLYPEPTIDES | NOVARTIS AG (CH) | 2016-06-16 | — | — | US | disclosed |
| US-9340582-B2 | Bioconjugates of synthetic apelin polypeptides | NOVARTIS AG (CH) | 2016-05-17 | — | — | US | disclosed |
| US-20160108091-A1 | CYCLIC POLYPEPTIDES FOR THE TREATMENT OF HEART FAILURE | NOVARTIS AG (CH) | 2016-04-21 | — | — | US | disclosed |
| US-9266925-B2 | Cyclic polypeptides for the treatment of heart failure | NOVARTIS AG (CH) | 2016-02-23 | — | — | US | disclosed |
| US-20160030585-A1 | NOVEL FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | NOVARTIS AG (CH) | 2016-02-04 | — | — | US | disclosed |
| US-20150031604-A1 | CYCLIC POLYPEPTIDES FOR THE TREATMENT OF HEART FAILURE | NOVARTIS AG (CH) | 2015-01-29 | — | — | US | disclosed |
| US-20150030594-A1 | BIOCONJUGATES OF SYNTHETIC APELIN POLYPEPTIDES | NOVARTIS AG (CH) | 2015-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160030585-A1 | NOVEL FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | FABP1, FABP2, FABP3 | GPR84 236/4885FFAR1 10/4885FFAR4 18/4885 |
| US-12037378-B2 | Variant CD58 domains and uses thereof | CD2, CD58, CD2BP2 | GPR84 1136/4885FFAR1 2823/4885FFAR4 1857/4885 |
| US-20150031604-A1 | CYCLIC POLYPEPTIDES FOR THE TREATMENT OF HEART FAILURE | NPY1R, ACKR3, IAPP | GPR84 614/4885FFAR1 515/4885FFAR4 626/4885 |
| US-20170119851-A1 | METHODS OF TREATING ANOREXIA | CRH, VIP, GIPR | GPR84 366/4885FFAR1 1588/4885FFAR4 1814/4885 |
| US-20240066132-A1 | NOVEL FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | FABP1, FABP2, FABP3 | GPR84 236/4885FFAR1 10/4885FFAR4 18/4885 |
| US-11752211-B2 | Fatty acids and their use in conjugation to biomolecules | FABP1, FABP2, FABP3 | GPR84 278/4885FFAR1 10/4885FFAR4 19/4885 |
| US-20170107248-A1 | SITE SPECIFIC PROTEIN MODIFICATIONS | PTMS, DNPEP, ANPEP | GPR84 2073/4885FFAR1 3572/4885FFAR4 2832/4885 |
| US-20170233443-A1 | CYCLIC POLYPEPTIDES FOR THE TREATMENT OF HEART FAILURE | NPY1R, ACKR3, IAPP | GPR84 614/4885FFAR1 515/4885FFAR4 626/4885 |
| US-20240025993-A1 | CD19 BINDING MOLECULES AND USES THEREOF | CD22, BCL9, CD2 | GPR84 589/4885FFAR1 3521/4885FFAR4 3404/4885 |
| US-20160166634-A1 | BIOCONJUGATES OF SYNTHETIC APELIN POLYPEPTIDES | APLNR, AP1G1, VIP | GPR84 1147/4885FFAR1 498/4885FFAR4 906/4885 |
| US-20160108091-A1 | CYCLIC POLYPEPTIDES FOR THE TREATMENT OF HEART FAILURE | NPY1R, ACKR3, IAPP | GPR84 614/4885FFAR1 515/4885FFAR4 626/4885 |
| US-20150030594-A1 | BIOCONJUGATES OF SYNTHETIC APELIN POLYPEPTIDES | APLNR, AP1G1, VIP | GPR84 1147/4885FFAR1 498/4885FFAR4 906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.